/
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients - PowerPoint Presentation

tawny-fly
tawny-fly . @tawny-fly
Follow
352 views
Uploaded On 2018-12-16

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients - PPT Presentation

Program Goals The Incretin System Response to Oral Glucose Injected Incretinbased Agents GLP1 Receptor Agonists Oral Incretinbased Agents DPP4 Inhibitors Main Pathophysiological Defects in T2D ID: 742158

basal insulin references cont insulin basal cont references add liraglutide glargine agents oral lixisenatide incretin glp inhibitors dpp abbreviations

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Injectable Options as Add-Ons to Basal I..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes PatientsSlide2
Slide3

Program GoalsSlide4

The Incretin System: Response to Oral GlucoseSlide5

Injected Incretin-based Agents: GLP-1 Receptor AgonistsSlide6

Oral Incretin-based Agents: DPP-4 Inhibitors Slide7

Main Pathophysiological Defects in T2DSlide8

T2D Anti-Hyperglycemic Therapy: General RecommendationsSlide9
Slide10

Approaches to Intensifying Therapy in Patients Not At Goal on Basal InsulinSlide11

Adding Prandial Insulin to Basal Insulin: Key Challenges Slide12

Scientific Rationale for Combining Basal Insulin with a GLP-1 agonistSlide13

DPP- 4 Inhibitors as Add-ons to Basal InsulinSlide14

Pramlintide as Add-on to Basal InsulinSlide15

Twice-daily Exenatide as Add-on to Basal Insulin (Glargine)Slide16

Twice-daily Exenatide as Add-on to Basal Insulin (Glargine): ResultsSlide17

Metformin plus Liraglutide Followed by Add-on of Basal Insulin (Detemir)Slide18

Metformin plus Liraglutide Followed by Add-on of Basal Insulin (Detemir)Slide19

Oral Agents Plus Basal Insulin (Glargine) Followed by Add-on Lixisenatide*Slide20

Oral Agents Plus Basal Insulin (Glargine) Followed by Add-on Lixisenatide* (cont)Slide21
Slide22

Other Safety Concerns With GLP-1 Receptor AgonistsSlide23

Lixisenatide* vs Liraglutide: Effect on Postprandial Glucose Levels†Slide24

Comparison of Basal Insulin + Lixisenatide* and Basal-Plus RegimensaSlide25

IDegLira* vs Degludec* or Liraglutide Alone: Effect on HbA1cSlide26

IDegLira* vs Degludec* or Liraglutide Alone: ResultsSlide27
Slide28

AbbreviationsSlide29

Abbreviations (cont)Slide30

ReferencesSlide31

References (cont)Slide32

References (cont)Slide33

References (cont)Slide34

References (cont)Slide35

References (cont)Slide36

References (cont)Slide37

References (cont)Slide38

References (cont)Slide39

References (cont)Slide40

References (cont)Slide41

References (cont)Slide42